

30 September 2019

Tender results

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 14 October 2019 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Capecitabine	Tab 150 mg; 60 tab, blister pack	\$11.15	\$10.00	Capercit (Dr Reddy's)	1 February 2020	1 July 2020	Brinov (REX)
Capecitabine	Tab 500 mg; 120 tab, blister pack	\$62.28	\$49.00	Capercit (Dr Reddy's)	1 February 2020	1 July 2020	Brinov (REX)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Capecitabine	Tab 150 mg; 60 tab, blister pack	\$11.15	\$10.00	Capercit (Dr Reddy's)	1%	1 February 2020	1 July 2020	Brinov (REX)
Capecitabine	Tab 500 mg; 120 tab, blister pack	\$62.28	\$49.00	Capercit (Dr Reddy's)	1%	1 February 2020	1 July 2020	Brinov (REX)
Moxifloxacin	Inj 1.6 mg per ml, 250 ml bottle; 1 bottle	\$70.00	\$39.00	Moxifloxacin Kabi (Fresenius Kabi)	1%	1 November 2019	1 April 2020	Avelox IV 400 (Bayer)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Rocuronium bromide	Inj 10 mg per ml, 5 ml ampoule; 10 ampoule pack	\$25.95 vial	\$31.14 ampoule	Hameln (Max Health)	1%	1 March 2020	1 August 2020	DBL Rocuronium Bromide (Pfizer)

3. *Tenders awarded to pharmaceuticals where no brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Bupivacaine hydrochloride with fentanyl	Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag; 10 bag pack	\$305.00	Biomed (Biomed)	1%	1 November 2019	1 April 2020

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2017/18 Invitation to Tender, dated 2 November 2017, and
- the 2018/19 Invitation to Tender, dated 1 November 2018

2017/18 Invitation to Tender

Chemical name	Line item
Dorzolamide hydrochloride	Eye drops 2%

2018/19 Invitation to Tender

Chemical name	Line item
Iron sucrose	Inj 20 mg per ml, 5 ml ampoule
Lidocaine [lignocaine] hydrochloride with chlorhexidine	Gel 2% with 0.05% chlorhexidine, 10 ml urethral syringe
Moxifloxacin	Tab 400 mg
Noradrenaline	Inj 0.06 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.12 mg per ml, 100 ml bag

Chemical name	Line item
Noradrenaline	Inj 0.16 mg per ml, 50 ml syringe
Pantoprazole	Inj 40 mg
Pegfilgrastim	Inj 6 mg per 0.6 ml prefilled syringe
Pemetrexed	Powder for infusion, 100 mg
Sodium chloride	Aqueous nasal spray isotonic

For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.